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Strengths and limitations of this study
 ► The main strength and contribution of this study is 
the identification of critical parameters for establish-
ing cost-effectiveness of the early invasive strategy 
in elderly non-ST-elevation myocardial infarction 
(NSTEMI) patients.
 ► The model utilised data from a variety of sources. 
These included large published studies, previous 
economic evaluations and national surveillance 
data.
 ► Uncertainty was incorporated in multiple input pa-
rameters by using a second-order Monte Carlo prob-
abilistic sensitivity analysis and numerous scenarios 
were assessed in sensitivity analysis.
 ► The main limitations of the analysis stemmed from 
paucity of NSTEMI-specific and long-term data.
AbStrACt
background Non-ST-elevation myocardial infarction 
(NSTEMI) is the most common type of heart attack in 
the UK and it is becoming increasingly prevalent among 
older people. An early invasive treatment strategy may 
be effective and cost-effective for treating NSTEMI but 
evidence is currently unclear.
Objectives To assess the cost-effectiveness of the early 
invasive strategy versus medical management in elderly 
patients with NSTEMI and to provide guidance for future 
research in this area.
Methods A long-term Markov state transition model 
was developed. Model inputs were systematically derived 
from a number of sources most appropriate to a UK 
relevant analysis, such as published studies and national 
routine data. Costs were estimated from the perspective 
of National Health Service and Personal Social Services. 
The model was developed using TreeAge Pro software. 
Based on a probabilistic sensitivity analysis, a value of 
information analysis was carried out to establish the value 
of decision uncertainty both overall and for specific input 
parameters.
results In 2017 UK £, the incremental cost-effectiveness 
ratio of the early invasive strategy was £46 916 for each 
additional quality-adjusted life-year (QALY) gained, with 
a probability of being cost-effective of 23% at a cost-
effectiveness threshold of £20 000/QALY. There was a 
considerable decision uncertainty with these results. The 
value of removing all this uncertainty was up to £1 920 000 
annually. Most uncertainty related to clinical effectiveness 
parameters and the optimal study design to remove this 
uncertainty would be a randomised controlled trial.
Conclusion Based on current evidence, the early 
invasive strategy is not likely to be cost-effective for 
elderly patients with NSTEMI. This conclusion should be 
interpreted with caution mainly due to the absence of 
NSTEMI-specific data and long-term clinical effectiveness 
estimates.
IntrOduCtIOn
Acute coronary syndrome (ACS) is a major 
cause of mortality and morbidity in the 
UK and worldwide.1 It is comprised of 
three life-threatening conditions including 
ST-elevation myocardial infarction (STEMI), 
non-ST-elevation myocardial infarction 
(NSTEMI) and unstable angina (UA). While 
STEMI is considered to be the most acute 
form of heart attack,2 NSTEMI and UA are 
less obstructive, characterised by partial rather 
than complete blockage of coronary artery. 
For this reason, recommended management 
is the same and the conditions are commonly 
grouped as non-ST-ACS (NSTEACS). Out of 
the three types of ACS, NSTEMI is the most 
common, causing a significant burden to the 
National Health Service (NHS) and society in 
terms of mortality, morbidity and economic 
losses.3
The recommended treatments for 
NSTEACS include conservative manage-
ment (ie, by medication only) and early 
invasive strategy. An early invasive strategy 
can be defined as angiography followed by 
revascularisation, if appropriate. This latter 
procedure includes percutaneous coronary 
intervention (PCI) or coronary artery bypass 
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Figure 1 Markov model structure (where Post-MI refers 
to post myocardial infarction; Post-MI-Post-Stroke is post-
myocardial infarction and post-stroke; Death CVD/Non-CVD 
is death from cardiovascular causes/non-cardiovascular 
causes).
graft (CABG). Evidence increasingly shows that the early 
invasive strategy results in better clinical outcomes for 
higher risk patients with NSTEACS both in the short-
term and long-term.4–6 The largest improvements are 
reported in the highest risk groups (ie, those with a 
thrombolysis in myocardial infarction7 (TIMI) score >2).5 
Out of all potential risk-factors, older age poses one of 
the greatest risks for NSTEMI. According to an analysis 
of a national registry containing 616 011 ACS events, 
in-hospital mortality is 10 times higher for those aged 
between 75 to 84 and 18 times higher for patients aged 
85+ compared with those younger than 55.8 Even though 
older patients are 30% to 40% of the NSTEMI popula-
tion, and have the greatest potential to benefit from an 
invasive therapy,9 they are often denied coronary revas-
cularisation due to the perceived high risk of in-hospital 
mortality and bleeding complications.10 Such decisions 
may not be best for patients and may be waste of scarce 
healthcare resources, if invasive therapy were shown to be 
cost-effective.
To address this, a comparison of the costs, effects and 
cost-effectiveness of the early invasive strategy is neces-
sary.11 This paper reports the first evaluation of the 
cost-effectiveness of early invasive strategy compared 
with conservative management in elderly patients with 
NSTEMI and also aims to determine what research is still 
needed to provide definitive guidance to practitioners, 
patients and the public.
MethOdS
A long-term Markov state transition model was developed 
to estimate the long-term cost-effectiveness of the early 
invasive versus the conservative strategy. The cycle length 
was 1 year. The modelling process was carried out using 
TreeAge Pro R2.1 (Williamstown, Massachusetts, USA)12 
software and in accordance with the National Institute 
for Health and Care Excellence (NICE) reference case 
for economic evaluations.13 The perspective of the anal-
ysis was NHS and Personal Social Services. Costs were 
expressed in pound sterling at a 2016 to 2017 price base, 
and benefits were reported as quality-adjusted life-years 
(QALYs). Both costs and benefits were discounted at 
an annual rate of 3.5%, based on the NICE guidance.14 
This article is reported in accordance with Consolidated 
Health Economic Evaluation Reporting Standards.15
target population
The model was based on a hypothetical cohort of elderly 
people, with equal proportions of males and females, 
undergoing either conservative management or invasive 
treatment therapy. The mean starting age was 75 years.
Model structure
The model consisted of five mutually exclusive states 
‘stable’, ‘post-MI’, ‘post-stroke’, ‘post-MI post-stroke’ and 
‘death’. A diagrammatical representation of the model is 
illustrated in figure 1 and the full structure, as used in the 
modelling software, is included in the online supplemen-
tary file 1.
All patients entered the model immediately after the 
post-index NSTEMI event health state (‘stable’). An 
individual could remain in this health state, die from 
other causes, experience a fatal or non-fatal stroke or 
myocardial infarction (MI). Depending on the events 
experienced an individual could move to the subsequent 
health states ‘post-MI’ after a non-fatal MI, ‘post-stroke’ 
after a non-fatal stroke, ‘dead’ for those patients dying 
or remained in the ‘stable’ state. Once in a ‘post-MI’ 
or ‘post-stroke’ health state, the individual could either 
remain in the states (by either experiencing no event or 
a recurrent event) or progress to the combined ‘post-MI 
post-stroke’ state (by experiencing a different type of 
event, for example, MI for post-stroke patients or vice 
versa) or die.
Model inputs
Baseline event rates
The two key events that could be experienced in each 
non-death state of the model were MI and stroke. For 
MI, the baseline event rates were derived from a large 
UK-based Third Randomised Intervention Treatment of 
Angina trial (RITA-3).6 For stroke, the average baseline 
event probability was calculated using a cardiovascular 
disease risk calculator QRISK2 in which age-specific UK 
general population characteristics,16 derived from Health 
Survey England,17 were applied, starting from the age of 
75 (our target population). In order to derive the annual 
probability of stroke in population with heart disease, the 
10-year risks were converted to annual risks and inflated 
by the hazard ratio of stroke in ACS patients relative to 
the general population.
The model structure also allowed the possibility of 
recurrent events of MI and stroke (excluding the index 
NSTEMI event). These were derived from Smolina et al18 
with the sample size of nearly 390 000 individuals. Simi-
larly, the annual rate of recurrent stroke was a based on a 
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large national General Practice Research Database study19 
which reported the long-term risks of stroke recurrence 
in the UK setting.
Mortality
UK national life tables were used to determine the prob-
ability of all-cause death for all ages with standardised 
mortality ratios (SMRs) of NSTEACS, MI and stroke used 
to adjust mortality for the ‘stable’, ‘post-MI’ and ‘post-
stroke’ states, respectively. For the combined ‘post-MI 
post-stroke’ state the SMR was estimated using the addi-
tive method.20
The model also included the possibility of operation 
related mortality following revascularisation. Based on 
national registries for cardiac surgery,21 22 a risk of 1.1% of 
death within 30 days after PCI or CABG was used. This was 
calculated as the weighted average of in-hospital mortality 
using the ratio of PCI to CABG which is approximately 
11:1, and which represents the current practice for the 
NSTEMI population in the UK.23
Effectiveness
The clinical benefits of the early invasive strategy were 
evaluated in terms of its effects on MI and stroke. In order 
to estimate the difference in MIs between the two arms, 
we used the results of a large, most recent and nation-
ally representative RITA-3 trial6 comparing early inva-
sive strategy to conservative management (mean age=63 
years).24 The trial reported incidence of MI for 1 and up 
to 5 years. Having two data points (at 1 and 5 years) in 
both conservative and invasive arms, and given that the 
survival curves were not parallel (as illustrated in RITA-3 
results25) meaning that proportional hazards could not be 
applied, resulted in the decision to extrapolate the rates 
in each arm by applying Weibull survival functions.26 The 
MI incidence curves and the values used for extrapolation 
and the resulting parameters are illustrated in the online 
supplementary files 2 and 3, respectively. The relative risk 
of stroke was obtained from a meta-analysis conducted 
as a part of Cochrane review comparing routine inva-
sive versus conservative strategies (mean age=67 years, so 
slightly younger that our modelled cohort).27
Resource use and costs
Annual costs in pound sterling were estimated for each 
state in the Markov model. The main sources of data were 
national routine sources, such as the NHS reference costs 
2016 to 2017,28 British National Formulary29 and the unit 
costs of health and social care30 and previous economic 
evaluations.31 32 Where necessary, the costs were inflated 
to 2017 price level.
Model state costs
For the ‘stable’ state, a micro-costing exercise was under-
taken to estimate the annual cost of medications and 
general practitioner (GP) visits. Based on a previous 
economic evaluation, three visits were assumed.19
The cost for the ‘post-MI’ was based on event rates 
from the Myocardial Ischaemia National Audit Project 
(MINAP) data set multiplied by their respective unit 
costs from NHS reference costs and included the costs 
of secondary prevention medication; the cost of acute MI 
was derived from the study by Palmer et al,31 as it is the 
most commonly referenced cost for MI.33
The cost of both acute stroke and the ‘post-stroke’ state 
were obtained from the Sentinel Stroke National Audit 
Programme which was judged to be the most reliable 
source of costs for this condition.34
In relation to fatal events, the costs of fatal MI and stroke 
were estimated from a range of UK-specific burden-of-
illness papers. These estimates have been used by other 
health technology assessments in cardiovascular disease 
area.35
Intervention costs
The costs of revascularisation (ie, PCI and CABG) were 
derived from the NHS reference costs.28 Since the unit 
cost of angiogram was not available in the NHS reference 
costs, this estimate was based on a survey of five hospitals 
in the UK, conducted as a part of the RITA-2 trial.36
Utilities
In order to calculate QALYs, each of the health states 
included in the Markov model had a utility value asso-
ciated with it. The utility values for ‘stable’ and ‘post-
MI’ states were sourced from a recent NICE technology 
appraisal focusing on ACS management.33 This source 
was chosen because the authors of the technology 
appraisal had conducted a literature review of health-re-
lated quality of life data that are applicable to NSTEACS 
population in the UK. Utilities for stroke were calculated 
based on a utility mapping study.37 The utilities for ‘post-
stroke’ and ‘post-MI’ states were combined by the multi-
plicative method. This method for combining utilities was 
recommended by NICE.38
Table 1 illustrates all input parameters used in the 
model. It is important to note that, since standard errors 
were unavailable for most of the parameters, the majority 
of the values were fixed.
Utility decrements due to negative treatment effects 
such as bleeding were not modelled explicitly. This is 
because for all state costs and utilities average values 
for the patient population were used, which accounted 
for the proportion of patients who experienced adverse 
events associated with the treatment. Decrements by age 
were considered in a sensitivity analysis.
Patient and public involvement
Additional patient and public involvement (PPI) was 
not sought for this work but we built on PPI work in 
the SENIOR-RITA trial. PPI in this trial was included 
through VOICENorth - an internal partner organisa-
tion comprising a network of citizens who contribute 
to research at Newcastle University. The lay summary 
of the SENIOR-RITA protocol was presented to the 
VOICENorth Research Support Group. One member of 
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Table 1 Model inputs
State/event/procedure Probability (SE) Distribution used in PSA Source
MI (control) 0.05 (age-dependent) – Fox et al6 25
MI (intervention) 0.04 (age-dependent) – Fox et al6 25
Stroke 0.02 (age- and sex –dependent) – Craig et al17
NICE33
Recurrent MI 0.03(0.0006) Normal Smolina et al18
Recurrent stroke 0.11 (age-dependent) – Mohan et al42
Relative risk (RR)       
RR (stroke) 0.83 (0.52) Log-normal Fanning et al27
Mortality       
Baseline probability of death 0.03 None as based on population level 
data
Office for National 
Statistics43
SMR for NSTEMI
 ► Year 1
 ► Subsequent years
  5.21
  1.97
None as based on population level 
data
NICE33
SMR for post-MI
 ► Year 1
 ► Subsequent years
  5.84
  2.21
  As above NICE33
SMR for post-stroke 2.3 (0.20) Log-normal Hankey44
SMR for post-MI post-stroke
 ► Year 1
 ► Subsequent years
  8.67
  5.51
  
  –
  –
NICE33
Hankey44
Probability of fatal MI 0.38 (increases with age) – Smolina et al18
Probability of fatal recurrent MI 0.34 (increases with age) – Smolina et al18
Probability of fatal stroke 0.13 Beta (n=9710; n=74 307)* Bray et al45
Probability of fatal recurrent stroke 0.16 – Lee et al19
Operative mortality 0.01† – NICOR21 22
State/procedure Cost (£) (SE)     
Stable 220 – NICE46
BNF29
PSSRU30
Post-MI 280 – NICE46
Post-stroke 5800 – SSNAP34
Post-MI post-stroke 6080 – NICE46
SSNAP34
Acute MI 6236 (2495) Gamma Palmer et al31
Acute stroke 22 000 – SSNAP34
Fatal MI 1200 – Greenhalgh et al32
Fatal stroke 2200 – Greenhalgh et al32
Angiogram 1053 (256) Gamma RITA-236
PCI 1992 (618) Gamma NHS reference costs28
CABG 9752 (2977) Gamma NHS reference costs28
Revascularisation (PCI/CABG) 4033 – NHS reference costs28
State/Event Utility (SE) Distribution used in PSA Source
Stable 0.842 (0.002) Beta NICE33
Post-MI 0.821 (0.038) Beta NICE33
Post-stroke 0.702 (0.014) Beta Whynes et al37
Kalra et al47
Post-MI and post-stroke 0.576(0.014) Beta NICE33
Whynes et al37
Kalra et al47
Continued
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Figure 2 Cost-effectiveness acceptability curves.
State/event/procedure Probability (SE) Distribution used in PSA Source
*Where n=the number of events; n=total sample.
†As these data relate to a younger age group (average age of operative mortality is 66 years for CABG and 65 years for PCI), we have conducted a sensitivity 
analysis where the operative mortality is an illustrative 10%.
BNF, British National Formulary; CABG, coronary artery bypass graft; MI, myocardial infarction; NICE, National Institute for Clinical Excellence; NICOR, National 
Institute for Cardiovascular Outcomes Research; PCI, percutaneous coronary intervention; PSA, Probabilistic Sensitivity Analysis; PSSRU, Personal and Social 
Services Research Unit; SMR, standardised mortality ratio; SSNAP, Sentinel Stroke National Audit Programme; STEMI, ST-elevation myocardial infarction.
Table 1 Continued
the group was invited to participate as a Trial Steering 
Committee lay member.
Link to the PPI group: https://www. ncl. ac. uk/ ageing/ 
partners/ internal_ ageing/ voice/
AnAlySIS
The joint estimates of costs and effects were combined 
in an incremental analysis between two strategies, and 
presented as the point estimate of mean incremental 
cost-effectiveness ratio (ICER) for early invasive versus 
conservative management. The ICER was calculated 
as difference in costs divided by difference in effects 
(QALYs) between the two interventions.
Both probabilistic (with 10 000 iterations) and deter-
ministic sensitivity analyses were used to explore param-
eter and other forms of uncertainty surrounding estimates 
of cost-effectiveness. Six one-way sensitivity analyses 
were conducted to investigate the impact of varying key 
assumptions and/or parameter values used in the base-
case analysis. Additionally, a series of deterministic sensi-
tivity analyses using low values of −25% and high values 
of +25% were also undertaken for all variables without 
prespecified distributions in order to investigate their 
relative impact on the results. The results of the analyses 
were presented in a Tornado diagram.
Threshold analyses were also conducted for the effec-
tiveness parameters, relative risk (RR) of stroke, proba-
bility of MI in the invasive arm and RR of MI (used in 
sensitivity analysis), in order to identify the values they 
would need to take in order for the invasive strategy to be 
cost-effective.
Finally, a value of information analysis was conducted 
in order to determine the value of future research overall 
as well as for specific parameters or groups of parameters. 
The resulting estimates were expressed as expected value 
of perfect information (EVPI) and the expected value of 
partial perfect information (EVPPI), respectively. The 
analysis was carried out using an online tool, Sheffield 
Accelerated Value of Information.39
reSultS
The model predicted mean life time costs of £8799 (95% 
credible interval (Crl) £7,934 to £9,790) and £9478 (95% 
Crl £8,331 to £10,773) and QALYs were 5.14 (95% Crl 5.09 
to 5.18) and 5.15 (95% Crl 5.10 to 5.20) for the conser-
vative and early invasive strategies, respectively. Thus, the 
resulting incremental cost per QALY for the early invasive 
strategy compared with conservative management was 
£46 916 per QALY gained. According to the probabilistic 
sensitivity analysis, the conservative management has a 
77% chance of being cost-effective when society is willing 
to pay £20 000 per QALY, as illustrated by the cost-ef-
fectiveness acceptability curve in figure 2. These results 
appear to be robust based on the one way sensitivity 
analyses which tested the importance of varying the key 
drivers of the model results. These included the relative 
risks of stroke and MI, length of treatment effectiveness, 
stroke-related mortality, rates of revascularisation and 
utilities. In every alternative scenario the invasive strategy 
was less cost-effective than in the base case analysis. Thus, 
none of these changes were found to affect the optimal 
treatment decision. Results of the deterministic sensitivity 
analyses can be found in the online supplementary file 4.
According to the additional sensitivity analyses which 
investigated the impact of varying the variables without 
predefined distributions, model results are most sensi-
tive to varying the probabilities of MI in both the control 
and the intervention arms (ie, variables relating to inter-
vention effectiveness). The impact of varying other vari-
ables is relatively minor. This is illustrated in the Tornado 
diagram (figure 3).
In the threshold analyses we identified the values which 
the effectiveness variables would need to take at the 
point when the intervention just becomes cost-effective 
(assuming a value of £20 000 for society’s willingness to 
pay for a QALY). For the threshold analyses, the values 
that the probability of MI in the invasive arm, RR stroke 
and RR MI would need to take are implausible (equal to 
0.01 and 0.53 and 0.40, respectively).
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Figure 3 Tornado diagram. ICER, incremental cost-effectiveness ratio; MI, myocardial infarction.
Table 2 Value of information analysis results
Groups of 
parameters
Per person 
EVPPI per 
year (£)
EVPPI for 
UK per year 
(£)
EVPPI for 
UK over 20 
years (£)
Clinical 
effectiveness (RR 
stroke)
30.70 1 506 359 3 012 715
Costs 0.08 4333 86 667
Utilities 0 0 0
EVPPI, expected value of partial perfect information; RR, relative 
risk.
Value of information analysis
Assuming that the number of people affected by the deci-
sion about the early invasive versus conservative strategy per 
year in the UK is 49 071 (the reported annual incidence of 
NSTEMI,40) then the total EVPI per year is £1.92 million for 
the UK. Assuming these technologies will be used for the 
next 20 years, the EVPI is £38.30 million. This is the value of 
removing all decision uncertainty about which treatment is 
cost-effective. Results from the EVPPI showed that the most 
important areas were those relating to the relative effective-
ness of interventions. This is illustrated in table 2.
dISCuSSIOn
One of the aims of this study was to evaluate the cost-ef-
fectiveness of the early invasive strategy in elderly patients 
with NSTEMI. The data for this model came from the 
best available sources and were rigorously assembled.
Using these data, the early invasive strategy was not 
cost-effective when compared with the conservative 
management. Nevertheless, the probabilistic sensitivity 
analysis results showed that, at the NICE willingness to 
pay threshold is £20,000, the early invasive strategy has a 
23% chance of being cost-effective when compared with 
the conservative management. The total value of informa-
tion over 20 years is £38.3 million and the main source of 
the uncertainty is around relative effectiveness of the two 
treatments. The optimal type of study to provide that data 
would be a randomised controlled trial comparing early 
invasive strategy to conservative management for elderly 
individuals with NSTEMI.
Our results are consistent with the clinical conclusions 
of a recent Cochrane review27 comparing the two treat-
ment strategies in patients with NSTEACS. The Cochrane 
review did not stratify patients based on their risk profiles 
but a previous economic evaluation by Henriksson et al 
has suggested that the invasive strategy was cost-effective 
only for those patients in the highest risk group.9
In terms of this study, there are several potential expla-
nations for the early invasive strategy being inferior to 
conservative management in terms of the cost-effective-
ness. First, only a fraction of patients received the addi-
tional benefits of the early invasive strategy due to the 
high baseline rates of angiography and revascularisation 
currently in the UK. Second, additional clinical effec-
tiveness in terms of reductions in MI and stroke were 
small on average, although CIs were wide (risk ratio 0.83, 
95% CI 0.34 to 1.86) indicating the considerable uncer-
tainty in rates of MI and stroke. A further reason that 
the early invasive strategy was not cost-effective was the 
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high background mortality in the ‘stable’ state (whereby 
patients had an initial NSTEMI but no subsequent events). 
This meant that a high proportion of people incurred the 
treatment costs but did not survive long enough to gain 
benefits of invasive treatment.
Strengths and limitations
Strengths
To our knowledge, this was the first economic evaluation 
comparing the early invasive versus conservative manage-
ment in the area of NSTEMI. The main contribution 
of the study is that, with rigorous attempts to structure 
the decision problem and to identify data, it has identi-
fied the critical parameters and thus the type of future 
research required to establish the cost-effective strategy 
for treating elderly patients with NSTEMI.
Another strength of this study is that almost all the input 
parameters that were used in the model were informed 
by the local evidence and results of this economic anal-
ysis should therefore be generalisable across the UK NHS. 
Furthermore, the analysis was conducted using best prac-
tice methods41 and used a comprehensive range of sensi-
tivity analyses to explore and characterise uncertainty. Our 
results remained robust in each of the explored scenarios.
Finally, model validation was ensured by carrying out a 
number of internal and external validation exercises in 
this way further reinforcing its conclusions. This process 
followed recommended best practice.41 A detailed summary 
of model validation and the overall modelling methodology 
is available online (online supplementary file 5).
Limitations
The model attempted to focus on NSTEMI population. 
However, despite extensive efforts to obtain data specific to 
this population relevant data for key model inputs were not 
available. For example, some model estimates came from 
studies which included people with UA. UA is a lower risk 
patient group, with less capacity to benefit from the invasive 
intervention.9 This may have biased our results against the 
early invasive intervention. Also, few data were available for 
longer term outcomes. Therefore, data on short-term effec-
tiveness (5 years or less) were used as the basis of extrapola-
tions. These shorter term data may have not fully reflected 
the benefits of the invasive intervention and may have thus 
biased the results against this strategy. A further potential 
bias against the invasive strategy may have arisen from the 
fact that the RITA-3 trial6 from which the effectiveness data 
were obtained was conducted nearly 20 years ago, and as 
such we may have overestimated the adverse outcomes in 
contemporary NSTEMI care.
In terms of biases favouring the invasive strategy, such bias 
might have arisen from the fact that patients in the conser-
vative arm in RITA-3 trial had very low rates of dual-anti-
platelet therapy (DAPT) compared with those in the 
invasive arm. Thus, any improvements in the invasive arm 
could arguably be attributed to the higher rates of DAPT.
Another limitation relating to the data used in the model 
is that measures of variance were only available for some of 
the parameters. The implication of this is that the EVPI is 
underestimated as the value of removing uncertainty around 
parameters, such as the state costs and baseline probabili-
ties, was not considered. For example, we could not explore 
the uncertainty around the probabilities of MI in each arm. 
This is because RITA-3 trial data suitable for constructing 
distributions was only available for the composite outcomes 
(MI or death). Thus, we were restricted in our ability to 
incorporate information into the probabilistic sensitivity 
analysis. Despite this limitation, the value of information 
analysis still showed considerable value in further research 
on the clinical effectiveness of treatments. Had we been 
able to incorporate the uncertainty surrounding these 
events, then we anticipate that the EVPI and EVPPI would 
be no less and possibly greater.
Finally, due to paucity of data, the model structure itself 
was limited. Specifically, it did not reflect the short-term 
treatment phase which was a common practice in other 
modelling studies. However, we attempted to address this 
limitation by incorporating the risk of operative mortality 
after undergoing revascularisation. This resulted in more 
conservative estimate of cost-effectiveness.
Overall, it is possible that the value of further research 
has been underestimated but given the uncertainties it 
remains most likely that further evidence on the relative 
effectiveness of treatments would be desirable.
COnCluSIOn
This study has presented the first cost-effectiveness 
analysis evaluating the early invasive strategy in elderly 
patients with NSTEMI. The results indicate that, in the 
long-term, the early invasive strategy is more costly but 
only marginally more effective than conservative manage-
ment and is therefore not cost-effective. However, given 
restrictions in the current evidence base, coupled with 
the results of our value of information analysis argue for a 
well-designed randomised controlled trial comparing the 
early invasive strategy to conservative management with a 
follow-up long enough to estimate longer term impacts.
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